Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Remnant cholesterol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Remnant cholesterol. Displaying page 1 of 1.
    EudraCT Number: 2004-002408-13 Sponsor Protocol Number: C LF 178P 0401 Start Date*: 2005-02-10
    Sponsor Name:FOURNIER Laboratories Ireland Ltd
    Full Title: A randomised, double-blind study comparing the efficacy and safety of 145mg NanoCrystal® fenofibrate, 10mg ezetimibe and their combination in patients with type IIb dyslipidemia and features of the...
    Medical condition: Patients with type IIb dyslipidemia and features of the metabolic syndrome.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024064-18 Sponsor Protocol Number: OM-EPA-003 Start Date*: 2011-03-22
    Sponsor Name:Omthera Pharmaceutical Inc.
    Full Title: Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia
    Medical condition: Severe hypertriglyceridemia defined as serum triglyceride (TG) values ≥500 and <2000 mg/dL (≥5.65 mmol/L and <22.60 mmol/L).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-003168-28 Sponsor Protocol Number: 77458 Start Date*: 2022-06-28
    Sponsor Name:Academic Medical Center (AMC), department of Internal Medicine
    Full Title: Impact of Triglyceride-Lowering on Inflammatory Activity in Patients with Hypertriglyceridemia
    Medical condition: - Hypertriglyceridemia - Inflammation - Lipoproteins
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006041-16 Sponsor Protocol Number: NK-104-310 Start Date*: 2006-06-30
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: DOUBLE-BLIND FOLLOW-ON STUDY OF PITAVASTATIN (4 MG) VERSUS ATORVASTATIN (20 MG AND 40 MG), WITH A SINGLE BLIND EXTENSION OF TREATMENT IN PATIENTS WITH TYPE II DIABETES MELLITUS AND COMBINED DYSLIPI...
    Medical condition: Combined Dyslipidemia and Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058110 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001518-39 Sponsor Protocol Number: K-877-303 Start Date*: 2017-01-16
    Sponsor Name:Kowa Research Institute, Inc.
    Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Pa...
    Medical condition: Severe hypertriglyceridemia [fasting TG levels >=500 mg/dL (5.65 mmol/L) and <2000 mg/dL (22.60 mmol/L) and mild or moderate renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-003511-37 Sponsor Protocol Number: K-877-301 Start Date*: 2017-01-16
    Sponsor Name:Kowa Research Institute, Inc.
    Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double­Blind, 12-Week Study With a 40-Week, Active-Controlled, Double­Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult ...
    Medical condition: severe hypertriglyceridemia [fasting TG levels >=500 mg/dL (5.65 mmol/L) and <2000 mg/dL (22.60 mmol/L)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-005075-40 Sponsor Protocol Number: 2013-005075-40 Start Date*: 2014-04-08
    Sponsor Name:Research Programs' Unit, Diabetes & Obesity, University of Helsinki
    Full Title: The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study.
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003818-26 Sponsor Protocol Number: K-877-302 Start Date*: 2017-03-16
    Sponsor Name:Kowa Research Institute, Inc.
    Full Title: Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes (PROMINENT)
    Medical condition: Reduction of cardiovascular events in patients with Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10012654 Diabetic complications cardiovascular HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Prematurely Ended) BG (Prematurely Ended) DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) HU (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001038-34 Sponsor Protocol Number: NK-104-305 Start Date*: 2006-02-03
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: STUDY OF PITAVASTATIN 4 MG vs. ATORVASTATIN 20 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH TYPE II DIABETES MELLITUS AND COMBINED DYSLIPIDEMIA
    Medical condition: Type II Diabetes Mellitus and Combined Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    7.1 10058110 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000641-13 Sponsor Protocol Number: BIO89-100-221 Start Date*: 2020-09-30
    Sponsor Name:89bio, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe Hypertriglyceridemia
    Medical condition: Severe Hypertriglyceridemia (SHTG)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001517-32 Sponsor Protocol Number: K-877-201 Start Date*: 2013-10-02
    Sponsor Name:Kowa Research Europe
    Full Title: A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels
    Medical condition: dyslipidemia (eg hyperlipidaemia, hypertriglyceridaemia)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) HU (Completed) DE (Completed) CZ (Completed) NL (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000065-16 Sponsor Protocol Number: DS102A-07-CV1 Start Date*: 2020-08-11
    Sponsor Name:Afimmune Ltd.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients with Hypertriglyceridemia and Type 2 Diab...
    Medical condition: Hypertriglyceridemia and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020870 Hypertriglyceridemia LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Nov 04 08:33:26 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA